SAN CARLOS, Calif., Aug. 28 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that it will hold the following events in September:
World Congress of Cardiology 2006 Barcelona, Spain Poster Session: “Tissue-factor/factor VIIa inhibition with higher-dose rNAPc2 reduces ischemia in patients with NSTE-ACS managed with an early invasive strategy in ANTHEM-TIMI 32" September 5, 2006 8:30 - 12:30 a.m. CEST Presenter: Robert P. Giugliano, M.D., S.M., investigator, TIMI Study Group, associate physician, Brigham and Women’s Hospital and assistant professor of medicine, Harvard Medical School Webcast to discuss Phase 2 rNAPc2, ANTHEM-TIMI 32, data in acute coronary syndromes (ACS) presented at the World Congress of Cardiology 2006 September 5, 2006 1:30 p.m. PT Steven Deitcher, M.D., vice president and chief medical scientist Ted W. Love, M.D., chairman and CEO Dial in: 866.713.8567 domestic and 617.597.5326 international with passcode 21826949 Replay: 888-286-8010 domestic and 617-801-6888 international with passcode 96057794, available through Tuesday, September 12, 2006 Webcast: www.nuvelo.com or visit the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents ( www.streetevents.com ), a password-protected event management site. BioCentury: NewsMakers in the Biotech Industry September 7, 2006 1:30 p.m. ET Ted. W. Love, M.D., chairman and CEO http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=NUVO&item_id=1376343 Cardiovascular and Interventional Radiological Society of Europe Bayer HealthCare AG sponsored satellite symposium “Advances in Thrombolytic Therapy: A Focus on Alfimeprase” September 11, 2006 11:45 a.m. CEST Moderator: Dr. Gunnar Tepe, associate professor of Radiology at the University of Tubingen Speakers: Dr. Barry Katzen, clinical professor of Radiology at the University of Miami School of Medicine and Dr. Steven Deitcher, vice president and chief medical scientist ThinkEquity Partners LLC 4th Annual Growth Conference September 13, 2006 3:00 p.m. PT Ward Wolff, senior vice president, finance and CFO http://www.wsw.com/webcast/tep10/nuvo/ Pharmaceutical Strategic Alliances Conference Panel: Geographic Issues in Licensing September 26, 2006 3:00 p.m. ET Moderator: Melanie Senior, Windhover Panelists: Ted W. Love, M.D., chairman and CEO, Nuvelo; William Hodder, vice president Business Development, Fibrogen; Alex Scott, vice president Business Development, Eisai Inc.
Live audio webcasts of the events and presentations will also be available online via the Investor Relations portion of Nuvelo’s website at www.nuvelo.com .
About Nuvelo
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic in four Phase 3 clinical trials for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex which recently completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical procedures. Nuvelo is also advancing an emerging oncology pipeline, which includes NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis, as well as rNAPc2 for potential use as a cancer therapy. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities. Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.
Nuvelo, Inc.
CONTACT: Nicole Estrin Foderaro, Associate Director of CorporateCommunications & IR of Nuvelo, Inc., +1-650-517-8472, ornfoderaro@nuvelo.com
Web site: http://www.nuvelo.com/
